Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ESDF | ISIN: US00972G2075 | Ticker-Symbol: CLA
Frankfurt
27.06.25 | 08:05
0,920 Euro
+1,10 % +0,010
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AKARI THERAPEUTICS PLC ADR Chart 1 Jahr
5-Tage-Chart
AKARI THERAPEUTICS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,9801,02011:52
0,9801,02011:05

Aktuelle News zur AKARI THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.06.Akari Therapeutics secures Indian patent for cancer drug payload2
AKARI THERAPEUTICS Aktie jetzt für 0€ handeln
18.06.Akari Therapeutics Plc: Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India416Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms India represents a...
► Artikel lesen
29.05.Akari Therapeutics Plc: Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology3
22.05.Akari Therapeutics Plc: Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar5
15.05.Akari Therapeutics Plc - 8-K, Current Report-
15.05.Akari Therapeutics GAAP EPS of $0.002
15.05.Akari Therapeutics Plc: Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update163Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with deep oncology experience by appointing...
► Artikel lesen
14.05.Akari Therapeutics Plc - 10-Q, Quarterly Report1
01.05.Akari Therapeutics ernennt neuen Leiter für Onkologie-Geschäftsentwicklung3
01.05.Akari Therapeutics appoints new head of oncology business1
01.05.Akari Therapeutics Plc: Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology217Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs...
► Artikel lesen
16.04.Akari Therapeutics GAAP EPS of $0.002
16.04.Akari Therapeutics Plc - 8-K, Current Report 2
15.04.Akari Therapeutics Plc - 10-K, Annual Report2
31.03.Akari Therapeutics Plc - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4054
20.03.Akari Therapeutics Appoints Abizer Gaslightwala President and CEO4
20.03.Akari Therapeutics names new CEO to drive cancer drug innovation2
20.03.Akari Therapeutics Plc - 8-K, Current Report3
20.03.Akari Therapeutics appoints Abizer Gaslightwala as CEO2
20.03.Akari Therapeutics Plc: Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer443Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have...
► Artikel lesen
Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1